PR Newswire
LONDON, March 19, 2026
LONDON, March 19, 2026 /PRNewswire/ — The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million by 2033, with a CAGR of 8.8% over the forecast period. This growth comes from increasing infertility rates, advances in genetic analysis technologies, and heightened awareness about hereditary diseases among prospective parents. Preimplantation genetic tests provide crucial insights that guide embryo selection, helping improve pregnancy outcomes and reducing miscarriage risks. Market dynamics show continued technological progress and expanding access to fertility care, supporting broader adoption worldwide.
https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
Key Highlights
- The global preimplantation genetic testing market is projected to reach US$ 1,081.9 Mn by 2033, expanding at a CAGR of 8.8% during the forecast period.
- Rising infertility rates and increasing maternal age are primary growth drivers, significantly boosting IVF and PGT adoption worldwide.
- Kits dominate the product segment, accounting for over 55% market share in 2026, supported by standardized workflows and automation compatibility.
- North America leads the market, driven by advanced IVF infrastructure and strong clinical adoption.
- Asia Pacific is projected to witness the fastest growth, fueled by expanding fertility clinics and supportive healthcare policies in China and India.
Request a Sample:
https://www.persistencemarketresearch.com/samples/34757
Rising Infertility and Advanced Maternal Age Boost Market Growth
Globally, delayed childbearing has increased infertility rates, heightening demand for assisted reproductive technologies (ART) including IVF. In England and Wales, the average age of first-time mothers rose from 23 in 1970 to 29 in 2020, while IVF procedures accounted for over 99% of ART cycles. In the U.S., around 16.6% of IVF cycles now involve PGT to screen embryos for chromosomal abnormalities, mitigating genetic risks. This trend fuels demand for reliable testing, with clinics adopting NGS and advanced embryo biopsy techniques to enhance accuracy and treatment outcomes. Rising awareness of hereditary conditions and regulatory frameworks in countries such as India under the PCPNDT Act further support market expansion. Fertility clinics increasingly integrate PGT into standard IVF protocols, enabling couples to make informed decisions and achieve higher live birth rates.
Technological Innovations and Automation Improve IVF Outcomes
Advancements in genetic technologies, such as next-generation sequencing (NGS) and AI-assisted embryo assessment, are transforming the PGT market. NGS offers comprehensive chromosome screening, boosting clinical pregnancy rates from 45.6% to 54.4% and live birth rates from 30.9% to 52.1% in studies of advanced maternal age patients. AI-driven image analysis predicts embryo viability with high accuracy, reducing diagnostic errors. Non-invasive PGT methods using cell-free DNA further minimize embryo damage while maintaining precision. Automation and integrated lab platforms streamline workflows, enhancing efficiency and reducing turnaround times. Clinics in North America and Europe are investing in digitalized PGT solutions, enabling personalized IVF treatments and improving patient outcomes.
Key Highlight: AI-Enabled PGT Advancements by CooperSurgical and Igenomix
- A notable development in the Preimplantation Genetic Testing (PGT) market is the advancement of AI-integrated genetic screening platforms by CooperSurgical and Igenomix. CooperSurgical’s PGTai℠ Technology Platform applies artificial intelligence and machine-learning algorithms to embryo biopsy data, supporting enhanced interpretation of PGT-A results. Meanwhile, Igenomix offers Smart PGT-A and Smart PGT-A Plus, which incorporate predictive algorithms to provide deeper chromosomal analysis and embryo assessment. These innovations aim to improve embryo selection processes and support informed clinical decision-making in IVF treatments.
- CooperSurgical brings extensive expertise in IVF laboratory technologies and reproductive solutions, while Igenomix contributes advanced genetic testing capabilities and bioinformatic analysis. Igenomix operates as part of the Vitrolife Group, strengthening its integration of genetics and embryology solutions. Both companies emphasize accuracy, data-driven insights, and workflow efficiency within fertility clinics. Their platforms are designed to provide reliable, standardized genetic reporting while supporting embryologists with AI-backed interpretation tools.
- These advancements address key challenges in IVF, including embryo selection uncertainty and variability in genetic result interpretation. By incorporating algorithm-based analysis, the technologies aim to enhance consistency, reduce subjectivity, and streamline laboratory operations. The integration of AI into PGT workflows reflects a broader industry shift toward precision-guided reproductive medicine and data-supported embryo viability assessment.
This signals accelerating adoption of AI-driven reproductive genetics solutions. Fertility clinics are increasingly prioritizing platforms that combine laboratory automation, genetic analytics, and predictive modeling. The growing use of AI-enabled PGT technologies sets a competitive benchmark in the market, encouraging further innovation focused on clinical accuracy, operational efficiency, and improved patient outcomes.
Request customization, ask for expert consulting, access a sample report, or simply express your interest–our team will assist you with the right insights and solutions: https://www.persistencemarketresearch.com/request-customization/34757
Segmentation Insights: Kits Segment Emerge as the Cornerstone of Growth
Kits lead the preimplantation genetic testing (PGT) market, supported by their standardized workflow, pre-validated reagents, and compatibility with next-generation sequencing platforms. Their pre-validated reagents and optimized protocols reduce human error and minimize reliance on highly specialized expertise, supporting wider adoption across fertility clinics. Their compatibility with automated systems and growing availability across advanced and emerging healthcare markets continue to strengthen segment growth. Recent developments around workflow optimization and integrated testing solutions further reinforce the strategic importance of kits within the PGT landscape.
Regional Insights: North America Leads Global PGT Adoption While Asia Pacific Emerges as the Fastest-Growing Innovation Hub
North America dominates the global preimplantation genetic testing (PGT) market, accounting for the largest revenue share, led by the strong performance of the U.S. market. Growth across the region is supported by advanced IVF infrastructure, high clinical adoption of genetic screening, favorable reimbursement frameworks, and substantial investment in genomics research. The presence of leading fertility networks and diagnostic innovators such as CooperSurgical strengthens technological advancement and commercial scalability. Rising maternal age and increasing prevalence of inherited disorders further sustain demand for early embryo screening. Meanwhile, Asia Pacific represents the fastest-growing region, driven by expanding access to fertility treatments, rising awareness of assisted reproductive technologies, and supportive government initiatives in China, India, and Japan. Rapid urbanization, healthcare infrastructure upgrades, and the emergence of cost-effective regional kit manufacturers are improving affordability, positioning Asia Pacific as a high-potential growth engine for the PGT market through 2033.
Key Players and Business Strategies
Leading players include CooperSurgical, Igenomix, Illumina, Fulgent Genetics, and Natera.
- CooperSurgical focuses on AI-integrated IVF solutions, enhancing procedural efficiency.
- Igenomix invests in automated genetic analysis platforms to expand clinic reach globally.
- Illumina emphasizes NGS-based PGT kits, enhancing test accuracy and throughput.
- Fulgent Genetics targets personalized IVF testing with rapid-result services.
- Natera develops non-invasive PGT solutions, minimizing embryo risk while ensuring precision.
Strategies across the market emphasize digital integration, personalized medicine, automation, and partnerships with fertility clinics to capture growing demand.
Buy Now: https://www.persistencemarketresearch.com/checkout/34757
Market Segmentation
By Product
- Kits
- Reagents and Consumables
By Technology
- Next-Generation Sequencing
- Fluorescence In Situ Hybridization
- Polymerase Chain Reaction
- Single-Nucleotide Polymorphism
- Comparative Genomic Hybridization
By Application
- Aneuploidy
- X-Linked Disorders
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- Gender Identification
- HLA Typing for Stem Cell Transplants
By Distribution Channel
- Hospitals
- Fertility Clinics
- Diagnostic Laboratories
- Academic & Research Institutions
- Others
Related Reports of
Biotechnology Market
Reports
Histology and Cytology Consumables Market
by Product (Kits & Reagents, Stains & Dyes, Enzymes, Fixatives, and Others), by Application (Clinical Diagnostics, Molecular Diagnostic Studies, Cell Signaling Studies, Epigenetics & Sequencing Studies, Drug Discovery & Development, and Research Applications) End-user (Hospitals, Diagnostic Laboratories, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations (CROs), and Academic & Research Institutes), and Regional Analysis from 2026 to 2033
Hemato Oncology Testing Market
by Product (Assay Kits, Reagents, Instruments / Platforms, Software & Services), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Immunohistochemistry (IHC), Others), Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Others), End-user, and Regional Analysis from 2026 – 2033
Rapid Microbiology Testing Market
by Product (Instruments, Reagents & Kits, Consumables, Software & Services), by Technology (Nucleic acid-based, Growth-based, Immunoassays & biosensors, ATP bioluminescence, Flow cytometry), by Application (Clinical diagnostics, Pharmaceutical & biologics testing, Food & beverage safety, Environmental testing, Cosmetics & personal care, Research & academic use), End-user and Regional Analysis, 2026 – 2033
Radiopharmaceutical Manufacturing Market
by Radioisotope (Technetium-99m, Other), Technology (Cyclotron-based Manufacturing, Other), Application (Oncology, Others), End-user, and Regional Analysis for 2026 – 2033
Hydrogel-based Drug Delivery System Market
by Source Type (Natural, Synthetic, Hybrid), Route of Delivery (Subcutaneous, Ocular, Others), Application (Cardiology, Others), End-user (Hospitals, Specialty Clinics, Others), and Regional Analysis for 2026 – 2033
CRISPR Gene-Editing Market
by Product (Kits & Enzymes, Libraries, Others), Service (gRNA Design and Vector Construction, Cell Line Engineering, Screening Services, Other), Application, and Regional Analysis, 2026 – 2033
Extracellular Matrix Patches Market
by Source (Porcine, Bovine, Others), by Application (Cardiac Repair, Vascular Repair, Soft Tissue Repair, Dural Repair, Orthopedic Repair, Wound Healing), End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), by Regional Analysis, 2026 – 2033
Platelet Rich Plasma Market
by Product (Pure Platelet Rich Plasma (Pure PRP), Leukocyte-rich Platelet Rich Plasma (L-PRP), Platelet Rich Fibrin (PRF), and Others), by Application (Orthopedics, Neurology, Cosmetics, Wound Care, and Others) by End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, and Academic and Research Institutes), and Regional Analysis from 2026 – 2033
Cellular Pathology Market
by Product Type (Diagnostic Kits, Others), Technology (Digital Pathology, Immunohistochemistry, Others), Application (Cancer Diagnostics, Infectious Diseases, Others), End-user, and Regional Analysis for 2026 – 2033
3D Cell Culture Market by Product (Medical Imaging Equipment, Operating Room & Surgical Equipment, Critical Care Devices, Patient Monitoring Devices, Neurology Devices, Cardiovascular Devices, Endoscopy Devices, and Others), Application (Cardiology, Neurology, Oncology, Orthopedics, Gynecology, and Others), End-user (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers (ASCs), and Specialty Clinics), and Regional Analysis from 2026 – 2033.
About Persistence Market Research:
At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we’ve been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.
Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today’s competitive environment.
Contact
Ritika KhandelwalPersistence Market ResearchSecond Floor, 150 Fleet Street, London, EC4A 2DQ+44 203-837-5656United KingdomUSA Phone – +1 646-878-6329Email: [email protected]
Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/preimplantation-genetic-testing-market-to-reach-us-1-081-9-million-by-2033-amid-rising-ivf-adoption-and-technological-innovation—persistence-market-research-302718707.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…